Abstract
Bisphosphonates are analogues of endogenous pyrophosphate and exhibit profound effects on bone metabolism. These compounds have been shown to inhibit the recruitment and/or activity of osteoclasts (bone-resorbing cells) and to increase bone mass by reducing both the activation frequency of new bone remodelling units and the depth to which osteoclasts resorb bone. In animal studies, several bisphosphonates (etidronate, tiludronate, pamidronate, and cimadronate (YM-175) have also produced beneficial biomechanical effects on bone (increases in bone strength, stiffness and fracture load) in conjunction with increases in bone mass. Because of the bisphosphonates' high affinity for bone, very few soft-tissue effects or toxicities are observed. Bisphosphonates have shown clinical efficacy in metabolic bone diseases such as Paget's disease, metastatic hypercalcaemia and postmenopausal osteoporosis, and their use is under investigation in other diseases of abnormal bone turnover such as glucocorticoid-induced oste...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
